Another indication of "medical fast reading society" Da hina (nilotini) was approved in China

Recently, the health and Health Commission of Liaoning Province issued the notice on printing and distributing the standardized management plan of vaccination in Liaoning Province, which will comprehensively improve the level of vaccination work in accordance with the "four strictest" requirements, and realize the standardization of vaccination units, the standardization of vaccination work, the informatization of whole process supervision and the gridding of grass-roots management (grassroots doctors' commune) On November 19, presidium health, a mobile healthcare company based in San Diego, California, completed a $3.5 million round a financing Presidium said it would use the new money to expand its doctor based services and build the stat platform, and it would use the money to promote its marketing plans (arterial network) On November 20, Novartis announced that recently, new indications of dahina ® (nilotinib), a product of Novartis tumor (China), have been approved by the State Drug Administration and can be used to treat chronic myeloid leukemia in children over 2 years old (Sina Medical News) On November 20, Bloomberg News reported that Novartis may acquire the medicines company that develops PCSK9 RNAi drug inclisiran, which makes mdco shares up 20% The news was not confirmed by two companies At the just concluded annual meeting of Aha, mdco released the detailed results of two three-phase clinical orion-9 and orion-10 of inclisiran, which confirmed the powerful lipid-lowering effect of twice a year (source of us and Chinese Medicine) On November 20, CDE official website showed that AstraZeneca selumetinib capsule had submitted clinical application in China It is worth noting that the new drug just submitted a new drug application to the US FDA on November 14 for the treatment of patients with type 1 neurofibromatosis related to 3-year-old and above plexiform neurofibroma These patients could not pass the surgical treatment and were awarded the priority evaluation qualification by the FDA (medicine cube) On November 20, according to the industry's self media Drug Newsletter, Nuo Chengjianhua announced that the National Drug Administration has accepted the application of new drugs for the treatment of relapsed / refractory chronic lymphoblastic leukemia (CLL) / small lymphoblastic lymphoma (SLL) patients by albuterol (icp-022) (Sina Medical News) On November 20, the review status of "bevacizumab bioequivalent drug" (acceptance No.: cxss1800017) of Qilu pharmaceutical was changed to "under approval" After two rounds of supplementary data and clinical and production site verification, it is predicted that it will be approved for market soon, which means that the first domestic bevacizumab bioequivalent drug will be successfully exported (Insight database) Today, alphazyme announced that the US FDA has granted its in-process drug arimoclomol breakthrough therapy to treat C-type Niemann peak disease The company plans to submit a new drug application to the FDA in the first half of 2020 (yaomingkant) Today, myovant Sciences announced that it was working on the GnRH receptor antagonist releuglix, which reached the primary end point and all key secondary end points in the three-stage study hero for patients with advanced prostate cancer Based on the positive results of the trial, myovant Sciences plans to submit a new drug application for releugolix to FDA in the second quarter of 2020 (yaomingkant) On November 19, ester Banque, head of intercontinental market of BMS, announced to employees that Chen Siyuan would join BMS on December 2, assume the post of general manager of mainland China and Hong Kong, report directly to the head of market in China and Asia, report the dotted line to the head of intercontinental market, and become a member of the intercontinental market leadership team Chen Siyuan was previously vice president and head of respiratory business of GlaxoSmithKline China (medical representative) In recent quarters, Amgen's revenue has been severely impacted by generic drugs, and the impact has now shifted to employee pay Last week, Amgen officially implemented the measure of cutting nearly 150 employees in the neuroscience business on the east coast of the United States On November 19, Amgen said it would cut another 172 employees in its headquarters and other business areas (Sina Medical News) On November 19, Yan'an Bikang announced that the company held a meeting on November 18, 2019 to consider and approve relevant proposals The company decided to shut down Jiujiu technology 7-ADCA product line and Jiangsu Jianding Biotechnology Co., Ltd to ensure the continuous operation and healthy development of Jiujiu technology Yan'an Bikang said that the closure of a subsidiary's product line was due to factors such as anti-dumping and environmental protection (cypress blue) On November 19, MSD and partner Bayer announced that their heart failure drug, soluble guanosine cyclase agonist, vericiguat, reached a composite primary end point consisting of hospitalization and cardiovascular death in an international multicenter phase III clinical trial called Victoria (source of us and Chinese Medicine) Recently, a new round of negotiation on medical insurance catalogue has been concluded, and the final result has not been officially announced On November 19, a person from the National Health Insurance Bureau told the Securities Daily that it would take a certain process to publish the final result in order to publish it this month (November) (Securities Daily) On November 18, Kangya Pharmaceutical Co., Ltd., a new third board pharmaceutical enterprise, issued a notice saying that it received the approval document of supplementary application for drugs on calcium dobesilate capsule approved and issued by the State Food and drug administration The drug became the first evaluated enterprise in China through the consistency evaluation of quality and efficacy of generic drugs, and the notice said that the company also became the first drug manufacturing enterprise in Northwest China through the consistency evaluation According to the data of minenet, in 2018, calcium dobesilate ranked first among the top 20 common names of terminal chemical oral blood vessel protectors in public medical institutions in China with an amount of 830 million yuan (meter net) Recently, the website of Qingdao Customs announced the decision of administrative penalty, which showed that Qingdao Customs imposed a penalty on Liaoning Pharmaceutical Foreign Trade Co., Ltd and its illegal fact was that the dangerous chemicals were exported without authorization without inspection The inquiry found that Liaoning Pharmaceutical Trade is a subsidiary of Shanghai Pharmaceutical Group Co., Ltd (China economic network)